PUMA BIOTECHNOLOGY, INC. (PBYI) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 405 transactions totaling $227.9M, demonstrating a bearish sentiment with -$118.6M in net insider flow. The most recent transaction on Feb 18, 2026 involved a transaction of 66,541 shares valued at $0.
No significant insider buying has been recorded for PBYI in the recent period.
No significant insider selling has been recorded for PBYI in the recent period.
Based on recent SEC filings, insider sentiment for PBYI is bearish with an Insider Alignment Score of 24/100 and a net flow of -$118.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at PUMA BIOTECHNOLOGY, INC. (PBYI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading PBYI stock, having executed 405 transactions in the past 90 days. The most active insider is Capital Partners Gp, L.l.c. Adage (Executive), who has made 20 transactions totaling $113.0M.
Get notified when executives and directors at PBYI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | F. Nougues Maximo | Chief Financial Officer | Award | 66,541 | $N/A | $0 | C-Suite |
| Feb 18, 2026 | F. Nougues Maximo | Chief Financial Officer | Award | 46,739 | $N/A | $0 | C-Suite |
| Feb 18, 2026 | M. Hunt Douglas | See Remarks | Award | 70,321 | $N/A | $0 | |
| Feb 18, 2026 | M. Hunt Douglas | See Remarks | Award | 49,394 | $N/A | $0 | |
| Feb 18, 2026 | H. Auerbach Alan | Executive | Award | 227,474 | $N/A | $0 | |
| Feb 18, 2026 | H. Auerbach Alan | Executive | Award | 159,778 | $N/A | $0 | |
| Jan 7, 2026 | F. Nougues Maximo | Chief Financial Officer | Sale | 6,405 | $5.88 | $37.7K | C-Suite |
| Jan 7, 2026 | M. Hunt Douglas | See Remarks | Sale | 5,014 | $5.88 | $29.5K | |
| Jan 7, 2026 | H. Auerbach Alan | Executive | Sale | 18,012 | $5.88 | $105.9K | |
| Jan 6, 2026 | F. Nougues Maximo | Chief Financial Officer | Sale | 4,540 | $5.84 | $26.5K | C-Suite |
| Jan 6, 2026 | M. Hunt Douglas | See Remarks | Sale | 3,973 | $5.84 | $23.2K | |
| Jan 6, 2026 | H. Auerbach Alan | Executive | Sale | 16,938 | $5.84 | $99.0K | |
| Nov 11, 2025 | Patrick Miller Michael | Executive | Sale | 20,000 | $4.86 | $97.2K | |
| Jul 18, 2025 | Cesano Alessandra | Executive | Sale | 27,000 | $3.37 | $91.0K | |
| Jul 9, 2025 | H. Auerbach Alan | Executive | Sale | 21,580 | $3.54 | $76.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 273 | $173.2M | 73.5% |
Purchase(P) | 34 | $54.7M | 23.2% |
Award(A) | 93 | $7.5M | 3.2% |
Exercise(M) | 5 | $429.4K | 0.2% |
Insider selling pressure at PUMA BIOTECHNOLOGY, INC. has increased, with 26 insiders executing 405 transactions across all time. Total sales of $173.2M significantly outpace purchases of $54.7M, resulting in a net outflow of $118.6M. However, 32% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.